血脂康治疗中老年原发性高脂血症的临床观察

[目的 ]　验证血脂康的调脂疗效和安全性并与辛伐他汀 (舒降之 )比较。　 [方法 ]　 2 86例中老年高脂血症患者随机分成两组。血脂康组 ( 160例 ,口服血脂康胶囊 1.2 g/d ,连服 12周 )和舒降之组 ( 12 6例 ,口服舒降之 10mg/d ,连服 12周 )治疗前后分别测定Tc ,TG ,HDL -c ,LDL -c ,APOA1,APOB和血、尿常规 ,血小板计数 ,肝、肾功能 ,肌酸激酶 ,血糖 ,心电图。　 [结果 ]　服药后 12周血脂康与舒降之两组均可有效地降低Tc ,TG、LDL -c且可升高HDL -c ,组内前后对照及组间比较差异均有显著性 (P <0 .0 1)。在升高APOA1和降低APOB比值上差异也有显著性 (P均 <0 .0 1)。服药期间未发现明显副作用。　 [结论 ]　血脂康的调脂疗效与舒降之相当。对脂质代谢具有综合性的调脂功能 ,是安全高效的国产调脂药物

Clinical observation of Xuezhikang in treating middle and old age hyperlipidaemias

Objective To observe the clinical effect and security of Xuezhikang in treating hyperlipidaemias and to contrast with that of Simvastatin. 286 patients were randomly divided into two groups, 160 cases in the Xuezhikang group(1.2g/d×12w) and 126 cases in the Simvastatin group (10mg/d×12w). Tc, TG, HDL-c, LDL-c, APOA, APOB, bloodplatelet, liver function , kidney function, CPK, blood sugar and ECG were determined before and after treatment. Tc,TG and LDL-c decreased and HDL-c increased in both groups (P <0.01). In regulating APOA/APOB the curative effect was significantly better in the Xuezhikang group than those in the Simvastatin group (P <0.01). [Conclusion] The clinical effect of Xuezhikang and Simvastatin in treatment of hyperlipidaemias was equal. Xuezhikang is a safe drug in treating hyperlipidaemias.